Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster good news likely on the wayy and if buyout then stock will explode …fum is super attractive here at ridiculous valuation of 26 million
Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster its in green again back to 20p quickly stock is oversold
Dirt low MC of £15 M /Cash ~£10.5 M / 3 Products in Pipeline including a Potential BIG Blockbuster starting to buy back my shares which i sold in the 20p area ,it was clear that stock would pullback after such a massive rally . Next major milestone will be the approval of tpr100 likely to happen next quarter and maybe we get some partnership news before the approval however stock is a pure gift at this price . Erectile dysfunction: giving patients more choice and better treatments Pharmaceutical Technology – 14 Feb 19 New treatments for erectile dysfunction: is MED2005 the ideal product? Futura Medical is currently developing a topical gel product as a new treatment; can MED2005 be among new treatments for erectile dysfunction? Futura Medical is optimistic about the outcome of this trial; it expects results to be published at the end of 2019 and for regulatory filings to follow in the second half of 2020.
The conundrum Approx 3 x that amount Tony
The conundrum Let’s hope it at least covers some of their salaries …350k doesn’t go very far… Depressing to see the price continue to slip, time to turn off till Summer.
The conundrum Indeed dermamax may be used under several different guises, when FUM registered Blue Diamond there were literally loads of products with that brand name. It takes approximately 4 months for tradenames to be registered which coincidentally will be the same time TPR approval will be received. I’m not quite sure if FUM have indicated how much part 2 will cost, maybe Aberdeen could throw some light. Also no idea what milestone amount we expect for TPR approval. Looks like Thornton & Ross paid £350k on signing the agreement in 2017, so most likely the approval should be much more.
The conundrum The milestone payment (whilst significant compared to historical payments that FUM have had) still is no where near what FUM would need for part 2 of phase 3. However as you say, if part 1 of phase 3 is good it puts FUM in a much stronger position for negotiating etc unlike the position we found ourselves in at the last dilution.
The conundrum Just read Aberdeen’s post I crossed over what he just said
The conundrum Even if they aren’t that confident in the milestone payment for TPR I’m sure they’re pretty confident about getting some positive phase 3 data. If they’re confident about that then they probably thought there’s no need to dilute the market even further. On the back of positive data they should be able to do a placing at a lot higher SP if the need for a part 2. You never know we might even get snapped up after part 1 if it’s positive. Let’s hope the milestone payment does materialise from TPR though that would put us in a pretty strong position going forward.
The conundrum If thats the case surely that may lessen the need for additional fund raises no? I’d be hoping anyone thats serious about picking this up would do so after 3a if data is good
The conundrum Lastemporer: P3 passes, but data isn’t good enough to submit for EU Reg approval… so FUM again go back to the market to do a placing to raise more money for P3 Part 2… and want to keep the asset tight in their hands until P3 P2 completes…basically same story all over again, with more dilution, more wait and again the market will know $$ will be needed for P3 part 2 so the Share price drifts lower quickly. If phase 3 data is good, the share price will shoot up regardless of whether we need a part 2. I think we should all assume part 2 will be needed. However if the phase 3 is good, then I believe any placing (if needed assuming funds are not sorted out beforehand) will be at a much higher price compared to 7p!! Also if the data is good enough it opens up many more doors than what FUM found itself in when it desperately needed the funds and had nowhere to turn to and we all know Lombard took full advantage of that. Get good phase 3 data and the tables are turned. Many more doors opened to raise funds if we needed to and the terms and conditions would not be entirely biased towards the other party… In summary, get good phase 3 data and we will be in a position of strength regardless of whether we need part 2 of phase 3.
The conundrum FUM receives (a substantial) milestone payment upon approval of TPR by the UK Regulatory body
The conundrum I think the volume has drastically reduced as the Day Trading Crowd have exited to another ‘play’ for now at least. I think as I expect most of us think, this stock will likely rise in anticipation of good results. If a second phase of P3 is required, there’ll definitely be a heavy drop but remember our lower baseline stock price should be far higher by then. I would guess that we’ll get a nice rise as we get into the period where people can add in this year’s ISA allowance. I wonder if the big pharma have any way of having a 'sneaky peak at the initial clinical trials data?! People who have access to this should already have a very good idea about the likelihood of a great pass/OK pass/fail. Don’t know if I’m being overly optimistic but to me, there seems to be an air of positivity in the management team at FUM (looking at their latest presentation to the analysts). Here’s hoping anyway! GLA
The conundrum Volume on the days has gone from millions down to a trickle. Seems like everyones in stand by mode unsure of whats to happen next. Definately logic would dictate hold your holding till just before results and then bank part of it just in case